Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results

RATIONALE: The M(1)/M(4) preferring muscarinic receptor agonist xanomeline demonstrated antipsychotic and procognitive effects in patients with Alzheimer’s disease or schizophrenia in prior studies, but further clinical development was limited by cholinergic adverse events (AEs). KarXT combines xano...

Descripción completa

Detalles Bibliográficos
Autores principales: Breier, Alan, Brannan, Stephen K., Paul, Steven M., Miller, Andrew C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102054/
https://www.ncbi.nlm.nih.gov/pubmed/37036495
http://dx.doi.org/10.1007/s00213-023-06362-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102054/
https://www.ncbi.nlm.nih.gov/pubmed/37036495
http://dx.doi.org/10.1007/s00213-023-06362-2

Ejemplares similares